Finally, we demonstrate here for the first time that KRAS-mutant cancer cell lines expressing elevated levels of MYC show increased sensitivity to several microtubule-interfering agents, opening up new avenues for therapeutic intervention and suggesting new strategies for patient stratification. This evidence concerns the gene KRAS and cancer.